Fig. 5.
Fig. 5. Lysis of renal carcinoma cells by MUC1-reactive CTL.M1.1 (A and C) and CTL.M1.2 (B and D). Human RCC cell lines A-498 (HLA-A2+/MUC1+), MZ1774-RCC (HLA-A2+/MUC1+), Caki-2 (HLA-A2−/MUC1+), ovarian cancer cell line SK-OV-3 (HLA-A2−/MUC1+), and K562 (HLA-A2−/MUC1+) were used as targets in a stardard 51Cr-release assay. The antigen specificity of the CTL lines was tested in the presence of unlabeled cold targets, T2 cells coated with the cognate, or an irrelevant peptide at an inhibitor:target ratio of 20:1 (C and D). For (A) and (B), (◊) K562; (▴) CAKI-2; (▹) SK-OV-3; (⧫) A498; (└) MZ1774-RCC. For (C) and (D), (▪) MZ1774-RCC + M1.1 peptide; (□) MZ1774-RCC; (○) MZ1774-RCC + T2-M1.1 peptide; (•) MZ1774-RCC + T2-E75 peptide.

Lysis of renal carcinoma cells by MUC1-reactive CTL.M1.1 (A and C) and CTL.M1.2 (B and D). Human RCC cell lines A-498 (HLA-A2+/MUC1+), MZ1774-RCC (HLA-A2+/MUC1+), Caki-2 (HLA-A2−/MUC1+), ovarian cancer cell line SK-OV-3 (HLA-A2−/MUC1+), and K562 (HLA-A2−/MUC1+) were used as targets in a stardard 51Cr-release assay. The antigen specificity of the CTL lines was tested in the presence of unlabeled cold targets, T2 cells coated with the cognate, or an irrelevant peptide at an inhibitor:target ratio of 20:1 (C and D). For (A) and (B), (◊) K562; (▴) CAKI-2; (▹) SK-OV-3; (⧫) A498; (└) MZ1774-RCC. For (C) and (D), (▪) MZ1774-RCC + M1.1 peptide; (□) MZ1774-RCC; (○) MZ1774-RCC + T2-M1.1 peptide; (•) MZ1774-RCC + T2-E75 peptide.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal